Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week High Following Analyst Upgrade

Maze Therapeutics, Inc. (NASDAQ:MAZE) reached a new 52-week high during trading on Friday after HC Wainwright raised their price target on the stock from $34.00 to $50.00. HC Wainwright currently has a buy rating on the stock. Maze Therapeutics traded as high as $25.50 and last traded at $24.80, with a volume of 5074476 shares trading hands. The stock had previously closed at $16.02.

MAZE has been the topic of several other research reports. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Wedbush initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 price target on the stock. Finally, BTIG Research lifted their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $30.17.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors have recently modified their holdings of the stock. CWM LLC bought a new position in shares of Maze Therapeutics during the 2nd quarter valued at $28,000. New York State Common Retirement Fund bought a new position in shares of Maze Therapeutics during the 1st quarter valued at $25,000. Legal & General Group Plc raised its holdings in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares in the last quarter. Corebridge Financial Inc. bought a new position in shares of Maze Therapeutics during the 1st quarter valued at $48,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Maze Therapeutics by 452.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after purchasing an additional 3,774 shares in the last quarter.

Maze Therapeutics Stock Performance

The business’s fifty day moving average price is $15.28 and its two-hundred day moving average price is $12.28.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.02.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.